旋风器加速器官网2023

旋风器加速器官网2023

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

旋风器加速器官网2023

Learn More
Folded page of a newspaper

旋风器加速器官网2023

旋风器加速器官网2023

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

旋风器加速器官网2023

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

旋风器加速器官网2023

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

旋风器加速器官网2023

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

旋风器加速器官网2023

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

旋风器加速器官网2023

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

酷通  旋风加速器16m版本  vnp加速  快交vpn  永远能连上网的vpn  旋风官网app  爱漫之家首页入口